tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Syndax price target raised to $38 from $35 at UBS
PremiumThe FlySyndax price target raised to $38 from $35 at UBS
1M ago
Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
Premium
Ratings
Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
1M ago
Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating
Premium
Ratings
Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating
1M ago
Syndax options imply 10.9% move in share price post-earnings
PremiumThe FlySyndax options imply 10.9% move in share price post-earnings
1M ago
Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025
Premium
The Fly
Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025
1M ago
SNDX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
SNDX Upcoming Earnings Report: What to Expect?
2M ago
Syndax price target raised to $27 from $26 at BofA
PremiumThe FlySyndax price target raised to $27 from $26 at BofA
2M ago
Buy Rating Reaffirmed for Syndax Pharmaceuticals Despite Black Box Warning on Revuforj
Premium
Ratings
Buy Rating Reaffirmed for Syndax Pharmaceuticals Despite Black Box Warning on Revuforj
2M ago
Buy Rating for Syndax Pharmaceuticals Driven by FDA Approval of Revuforj and Market Expansion Potential
Premium
Ratings
Buy Rating for Syndax Pharmaceuticals Driven by FDA Approval of Revuforj and Market Expansion Potential
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100